Do Tung Dac

Dr. Do Tung Dac

Kanazawa University, Kanazawa, Ishikawa, Japan
orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 May 2025 in International Journal of Hematology
Verified
Journal Article
Closed access
PDF file
DDDo Tung Dac
Do Tung Dac
HKHonoka Koshihara
Honoka Koshihara
MCMyongje Cho
Myongje Cho
PIPleiades Tiharu Inaoka
Pleiades Tiharu Inaoka
HNHoang Thao Giang Nguyen
Hoang Thao Giang Nguyen
Luis EspinozaLuis Espinoza
Luis Espinoza

28 September 2025 in Clinical and Experimental Obstetrics & Gynecology
Verified
Journal Article
Open access
TNThuy Thanh Nguyen
Thuy Thanh Nguyen
NLNgoc Anh Le
Ngoc Anh Le
DDDo Tung Dac
Do Tung Dac
TNThi Ngoc Dung Ngo
Thi Ngoc Dung Ngo
SDSon Hai Doan
Son Hai Doan
TNThi Ngoc Thao Nguyen
Thi Ngoc Thao Nguyen
Background: Preeclampsia (PE), a severe pregnancy complication, is a major contributor to maternal and perinatal morbidity and mortality worldwide. Matrix metalloproteinases (MMPs) and their tissue inhibitors of metalloproteinases (TIMPs) are implicated in the pathogenesis of PE. This study aimed to evaluate maternal plasma levels of MMP-2, MMP-3, MMP-9, TIMP-1, and TIMP-2 in normal and preeclamptic pregnancies across gestational trimesters to assess their predictive value. Methods: This case-control study included a total of 138 pregnant women: 72 with normal pregnant women (controls) and 66 women diagnosed with PE, recruited at Hanoi Obstetrics and Gynecology Hospital between July 2022 and June 2024. In the second trimester (14–28 weeks), the PE and control groups included 14 and 18 women, respectively. In the third trimester (29–41 weeks), the study included 52 women with PE and 54 controls. Plasma concentrations of MMP-2, MMP-3, MMP-9, TIMP-1, and TIMP-2 were measured using enzyme-linked immunosorbent assay (ELISA). Correlations between MMPs, TIMPs, MMP/TIMP ratios, and PE severity indices were analyzed using Spearman’s correlation. Receiver operating characteristic (ROC) analysis evaluated the diagnostic and predictive utility of these markers. Results: Maternal plasma levels of MMP-2 and TIMP-2 were significantly higher in the PE group compared to controls during both the second and third trimesters (p < 0.05). The MMP-2/TIMP-2 ratio was significantly lower in the PE group during the third trimester (p = 0.002). MMP-3 levels were markedly elevated in PE patients (p < 0.001) and were positively correlated with plasma creatinine and proteinuria. In contrast, MMP-9 levels were significantly reduced in the PE group across both trimesters (p < 0.05), whereas TIMP-1 levels showed no significant difference between groups. Notably, MMP-9 was strongly correlated with TIMP-1 in PE, and both markers correlated with systolic blood pressure (SBP). ROC curve analysis indicated the combination of MMP-2 and TIMP-2 as the best predictor of PE in the second trimester, while TIMP-2 was the most predictive marker in the third trimester. Conclusions: Elevated plasma MMP-2 and TIMP-2 levels, particularly in the second trimester, show potential as biomarkers for identifying patients at risk of PE. TIMP-2 appears promising for prediction in the third-trimester. These findings warrant further investigation for potential clinical application.

6 January 2026 in Immunogenetics
Verified
Journal Article
Closed access
PDF file
NVNguyen Hoang Viet
Nguyen Hoang Viet
LDLe Thanh Dong
Le Thanh Dong
DDDo Tung Dac
Do Tung Dac
HLHai Ha Long Le
Hai Ha Long Le
LPLe Thi Phuong
Le Thi Phuong
Luis EspinozaLuis Espinoza
Luis Espinoza

9 May 2026 in Gene
Verified
Journal Article
Closed access
JNJulia Nakano
Julia Nakano
NVNguyen Hoang Viet
Nguyen Hoang Viet
HNHoang Thao Giang Nguyen
Hoang Thao Giang Nguyen
DDDo Tung Dac
Do Tung Dac
LHLe Ha Long Hai
Le Ha Long Hai
Luis EspinozaLuis Espinoza
Luis Espinoza

16 October 2025 in Expert Review of Clinical Immunology
Verified
Journal Article
Closed access
JEJ. Luis Espinoza
J. Luis Espinoza
DDDo Tung Dac
Do Tung Dac
NGNguyen Hoang Thao Giang
Nguyen Hoang Thao Giang
ATAkiyoshi Takami
Akiyoshi Takami
Interleukin-17 (IL-17), a proinflammatory cytokine primarily produced by Th17 cells, plays a complex role in transplant immunology. Its involvement in graft-versus-host disease (GvHD) and immune regulation following hematopoietic cell transplantation (HCT) has garnered significant clinical interest, though findings remain inconsistent. This narrative review summarizes clinical studies in human HCT recipients investigating IL-17 cytokine levels, Th17 cell activity, and IL-17 gene polymorphisms associated with transplant outcomes. While several studies report associations between elevated IL-17 or Th17 levels and increased GvHD risk, results vary widely due to differences in study design, patient populations, and measurement methods. IL-17 is a promising, though context-dependent, biomarker and therapeutic target in HCT. Its dual roles in promoting inflammation and supporting antimicrobial defense complicate therapeutic modulation. Future studies should focus on standardized assays, multi-omics approaches, and longitudinal designs to clarify its clinical utility. Tailored strategies that modulate IL-17 without impairing immune reconstitution or graft-versus-leukemia effects are likely to guide future interventions.

15 June 2026 in Marine Drugs
Verified
Journal Article
Open access
PDF file
SMShohei Mizuno
Shohei Mizuno
Luis EspinozaLuis Espinoza
Luis Espinoza
LVLam Quang Vu
Lam Quang Vu
HBHirona Banno
Hirona Banno
YIYusuke Iida
Yusuke Iida
Akiyoshi TakamiAkiyoshi Takami
Akiyoshi Takami
Background: Ascophyllan, a sulfated polysaccharide extracted from brown seaweed, has shown immunomodulatory and antioxidant effects in preclinical studies, yet human clinical evidence remains scarce. This randomized, double-blind, placebo-controlled pilot trial evaluated the safety and exploratory biological effects of daily ascophyllan supplementation in healthy adults. Methods: Twelve participants were randomized to receive either ascophyllan (n = 6) or placebo (n = 6) for 28 days. Safety was monitored through adverse event reporting and repeated laboratory assessments, including hematology, biochemistry, and inflammatory markers. Immune cell populations were analyzed via serial flow cytometry, serum total antioxidant capacity was measured at multiple time points, and gut microbiome composition was profiled using 16S rRNA gene sequencing. All analyses were exploratory in nature. Results: Ascophyllan supplementation proved well tolerated, with no adverse events observed and stable hematologic, renal, and biochemical parameters throughout the study. Exploratory longitudinal analyses suggested directional modulation of NK-cell-associated phenotypes during ascophyllan supplementation, including directional changes in CD57+, NKp46+, and NKG2D+ NK-cell phenotypes; however, group × time interaction analyses did not remain statistically significant after correction for multiple comparisons. Serum antioxidant capacity showed inter-individual variability with a directional but non-significant increase in the ascophyllan group at intermediate time points. Exploratory microbiome analyses suggested modest directional compositional differences involving members of the Bacteroidaceae and Bifidobacteriaceae families; however, no taxon remained statistically significant after correction for multiple comparisons. Conclusions: These preliminary findings indicate that ascophyllan is safe and well tolerated in healthy adults and may be associated with modulation of innate immune phenotypes, subtle microbiome compositional differences, and directional changes in antioxidant capacity. Larger, adequately powered clinical trials are warranted to confirm these observations and further investigate potential biological and clinical effects.